ReviewAntibiotics (Basel, Switzerland)2020
Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 79 citations in OpenAlex.
- Development andMicrobiology spectrum · 2026Article
- Unveiling Novel Lytic Bacteriophages as Natural Biocontrol Agents Against Multidrug-Resistant Escherichia coli: Isolation, Characterization, and In vitro Application.Food and environmental virology · 2026Article
- Environmental isolation and characterization of Escherichia coli phages from Burkina Faso.BMC microbiology · 2026Article
- Can phage-antibiotic combinations overcome uropathogenic Escherichia coli regrowth? evidence from in vitro and in vivo models.Virology journal · 2026Article
- Distribution of acquired carbapenemase genes among uropathogenic Escherichia coli.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Genomic and functional characterization ofFrontiers in microbiology · 2026Article
- Characterization and genome analysis of jumbo Escherichia phage UE-S1 and the antibacterial potential of its lysozyme against uropathogenic E. coli.BMC microbiology · 2025Article
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Characterization and therapeutic potential of phage vB_Eco_ZCEC08 against multidrug-resistant uropathogenic Escherichia coli.BMC microbiology · 2025Article
- Rapid formulation of a genetically diverse phage cocktail targeting uropathogenic Escherichia coli infections using the UTI89 model.Scientific reports · 2025Article
- Review
- Detection of plasmid-mediatedInfectious diseases & immunity · 2025Article
- Drug susceptibility of uropathogens isolated from patients treated at the Mazovian Specialized Hospital in Radom.Acta biochimica Polonica · 2025Article
- Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections.Acta biochimica Polonica · 2025Review
- An Overview of the Association of the Urinary Tract Microbiome with Various Diseases and Implications for Therapeutics.Mini reviews in medicinal chemistry · 2025Review
- Addressing the global challenge of bacterial drug resistance: insights, strategies, and future directions.Frontiers in microbiology · 2025Review
- CRISPR/Cas9-Mediated Genome Editing of T4 Bacteriophage for High-Throughput Antimicrobial Susceptibility Testing.Analytical chemistry · 2024Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are regarded as one of the most common bacterial infections affecting millions of people, in all age groups, annually in the world. The major causative agent of complicated and uncomplicated UTIs are uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.